TNSN08064A1 - Albumin fusion proteins - Google Patents
Albumin fusion proteinsInfo
- Publication number
- TNSN08064A1 TNSN08064A1 TNP2008000064A TNSN08064A TNSN08064A1 TN SN08064 A1 TNSN08064 A1 TN SN08064A1 TN P2008000064 A TNP2008000064 A TN P2008000064A TN SN08064 A TNSN08064 A TN SN08064A TN SN08064 A1 TNSN08064 A1 TN SN08064A1
- Authority
- TN
- Tunisia
- Prior art keywords
- fusion proteins
- albumin fusion
- nucleic acids
- vectors
- host cells
- Prior art date
Links
- 102000009027 Albumins Human genes 0.000 title abstract 6
- 108010088751 Albumins Proteins 0.000 title abstract 6
- 102000037865 fusion proteins Human genes 0.000 title abstract 6
- 108020001507 fusion proteins Proteins 0.000 title abstract 6
- 102000039446 nucleic acids Human genes 0.000 abstract 4
- 108020004707 nucleic acids Proteins 0.000 abstract 4
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 239000013598 vector Substances 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70752105P | 2005-08-12 | 2005-08-12 | |
| US71238605P | 2005-08-31 | 2005-08-31 | |
| US73272405P | 2005-11-03 | 2005-11-03 | |
| US77691406P | 2006-02-28 | 2006-02-28 | |
| US78136106P | 2006-03-13 | 2006-03-13 | |
| US81018206P | 2006-06-02 | 2006-06-02 | |
| US81368206P | 2006-06-15 | 2006-06-15 | |
| PCT/US2006/029391 WO2007021494A2 (en) | 2005-08-12 | 2006-07-31 | Albumin fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TNSN08064A1 true TNSN08064A1 (en) | 2009-07-14 |
Family
ID=37758042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2008000064A TNSN08064A1 (en) | 2005-08-12 | 2008-02-11 | Albumin fusion proteins |
Country Status (13)
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| ES2484966T3 (es) | 2000-04-12 | 2014-08-12 | Novozymes Biopharma Dk A/S | Proteínas de fusión de albúmina |
| US20080194481A1 (en) | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| WO2003060071A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| CA2554089C (en) | 2004-02-09 | 2013-10-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| AU2007258609B2 (en) * | 2006-06-07 | 2013-01-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| BRPI0716744A2 (pt) * | 2006-09-14 | 2016-10-04 | Human Genome Sciences Inc | proteínas de fusão de albumina |
| EP2423219B1 (en) | 2007-01-30 | 2015-04-29 | Epivax, Inc. | Regulatory T cell epitopes, compositions and uses thereof |
| RU2567667C2 (ru) | 2008-06-13 | 2015-11-10 | Проекто Де Биомедисина Сима, С.Л. | Конъюгаты для введения биологически активных соединений |
| JP2012515222A (ja) | 2009-01-16 | 2012-07-05 | テバ ファーマシューティカル インダストリーズ リミテッド | 組換えヒトアルブミン−ヒト顆粒球コロニー刺激因子融合タンパク質の安定な製剤 |
| KR101722961B1 (ko) | 2009-02-11 | 2017-04-04 | 알부메딕스 에이/에스 | 알부민 변이체 및 접합체 |
| KR20100100254A (ko) * | 2009-03-05 | 2010-09-15 | (주)바이오큐어팜 | 인간 혈청 알부민-팀프-2 융합 단백질과 항암제를 포함하는암의 예방 또는 치료용 조성물 |
| WO2011028229A1 (en) | 2009-08-24 | 2011-03-10 | Amunix Operating Inc. | Coagulation factor ix compositions and methods of making and using same |
| CN105567699A (zh) | 2009-10-30 | 2016-05-11 | 诺维信生物制药丹麦公司 | 白蛋白变体 |
| EP2556087A1 (en) | 2010-04-09 | 2013-02-13 | Novozymes Biopharma DK A/S | Albumin derivatives and variants |
| WO2011146902A1 (en) | 2010-05-21 | 2011-11-24 | Merrimack Pharmaceuticals, Inc. | Bi-specific fusion proteins |
| EP3189835B1 (en) * | 2011-02-28 | 2018-07-25 | National Cerebral and Cardiovascular Center | Medical agent for suppressing malignant tumor metastasis |
| JP6430828B2 (ja) | 2011-05-05 | 2018-11-28 | アルブミディクス リミティド | アルブミン変異体 |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| WO2012170969A2 (en) | 2011-06-10 | 2012-12-13 | Biogen Idec Ma Inc. | Pro-coagulant compounds and methods of use thereof |
| CN104383541A (zh) | 2011-10-21 | 2015-03-04 | 艾伯维公司 | 用于治疗hcv的包含至少两种直接抗病毒剂和利巴韦林但无干扰素的方法 |
| DE202012012954U1 (de) | 2011-10-21 | 2014-08-12 | Abbvie Inc. | Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| HK1200842A1 (en) | 2011-11-18 | 2015-08-14 | Albumedix Ltd | Proteins with improved half-life and other properties |
| MY201293A (en) | 2012-01-12 | 2024-02-15 | Bioverativ Therapeutics Inc | Chimeric factor viii polypeptides and uses thereof |
| SG10201606783RA (en) | 2012-02-15 | 2016-10-28 | Amunix Operating Inc | Factor viii compositions and methods of making and using same |
| EP2822577B1 (en) | 2012-02-15 | 2019-02-06 | Bioverativ Therapeutics Inc. | Recombinant factor viii proteins |
| EP2825556B1 (en) | 2012-03-16 | 2018-01-03 | Albumedix A/S | Albumin variants |
| CA2875247A1 (en) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Chimeric clotting factors |
| AU2013270682A1 (en) | 2012-06-08 | 2014-12-11 | Biogen Ma Inc. | Procoagulant compounds |
| CN103525695B (zh) * | 2012-07-04 | 2015-05-20 | 长沙中生众捷生物技术有限公司 | 便携式肾功能检测系统 |
| CA2878679A1 (en) | 2012-07-11 | 2014-01-16 | Amunix Operating Inc. | Factor viii complex with xten and von willebrand factor protein, and uses thereof |
| EP2908847B1 (en) | 2012-10-18 | 2022-03-30 | Bioverativ Therapeutics Inc. | Methods of using a fixed dose of a clotting factor |
| CA2890766A1 (en) | 2012-11-08 | 2014-05-15 | Novozymes Biopharma Dk A/S | Albumin variants |
| EP2956477B2 (en) | 2013-02-15 | 2024-01-24 | Bioverativ Therapeutics Inc. | Optimized factor viii gene |
| AU2014217831A1 (en) | 2013-02-16 | 2015-07-16 | Albumedix Ltd. | Pharmacokinetic animal model |
| EP2968498A4 (en) | 2013-03-15 | 2016-09-07 | Biogen Ma Inc | FACTOR IX polypeptide formulations |
| CN113817069A (zh) | 2013-06-28 | 2021-12-21 | 比奥贝拉蒂治疗公司 | 具有xten的凝血酶可裂解连接子和其用途 |
| EP3033097B1 (en) | 2013-08-14 | 2021-03-10 | Bioverativ Therapeutics Inc. | Factor viii-xten fusions and uses thereof |
| EP3903599A1 (en) | 2013-09-25 | 2021-11-03 | Bioverativ Therapeutics Inc. | On-column viral inactivation methods |
| EP3065769A4 (en) | 2013-11-08 | 2017-05-31 | Biogen MA Inc. | Procoagulant fusion compound |
| SG10201805924PA (en) | 2014-01-10 | 2018-08-30 | Bioverativ Therapeutics Inc | Factor viii chimeric proteins and uses thereof |
| WO2016004113A1 (en) | 2014-06-30 | 2016-01-07 | Biogen Ma Inc. | Optimized factor ix gene |
| SG11201702934TA (en) | 2014-10-14 | 2017-05-30 | Halozyme Inc | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same |
| MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
| MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
| BR112018002150A2 (pt) | 2015-08-03 | 2018-09-18 | Bioverativ Therapeutics Inc | proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas |
| BR112018003179A2 (pt) | 2015-08-20 | 2018-09-25 | Albumedix As | conjugados e variantes de albumina |
| ES2863278T3 (es) | 2015-10-02 | 2021-10-11 | Silver Creek Pharmaceuticals Inc | Proteínas terapéuticas biespecíficas para la reparación de tejidos |
| CN105254766B (zh) * | 2015-10-26 | 2018-10-16 | 中国航天员科研训练中心 | 机械生长因子MGF E domain肽在调控记忆相关基因和miRNA表达中的应用 |
| RS63548B1 (sr) | 2016-02-01 | 2022-09-30 | Bioverativ Therapeutics Inc | Optimizovani geni faktora viii |
| WO2017189978A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| EP3535585A1 (en) | 2016-11-04 | 2019-09-11 | Aarhus Universitet | Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor |
| MA46967A (fr) | 2016-12-02 | 2019-10-09 | Bioverativ Therapeutics Inc | Méthodes de traitement de l'arthropathie hémophilique à l'aide de facteurs de coagulation chimériques |
| JP2019536794A (ja) | 2016-12-02 | 2019-12-19 | バイオベラティブ セラピューティクス インコーポレイテッド | 凝固因子に対する免疫寛容を誘導する方法 |
| WO2018112362A1 (en) | 2016-12-16 | 2018-06-21 | Biogen Ma Inc. | Stabilized proteolytically activated growth differentiation factor 11 |
| TW201831521A (zh) | 2017-01-31 | 2018-09-01 | 美商生物化學醫療公司 | 因子ｉｘ融合蛋白以及其製備方法及使用方法 |
| CN110770251A (zh) * | 2017-04-20 | 2020-02-07 | 诺和诺德股份有限公司 | 纯化白蛋白融合蛋白的方法 |
| KR102780287B1 (ko) | 2017-08-09 | 2025-03-14 | 바이오버라티브 테라퓨틱스 인크. | 핵산 분자 및 이의 용도 |
| AU2019215063A1 (en) | 2018-02-01 | 2020-09-03 | Bioverativ Therapeutics, Inc. | Use of lentiviral vectors expressing Factor VIII |
| RS66972B1 (sr) | 2018-05-18 | 2025-07-31 | Bioverativ Therapeutics Inc | Metode lečenja hemofilije a |
| CN114903978A (zh) | 2018-07-03 | 2022-08-16 | 百时美施贵宝公司 | Fgf-21配制品 |
| SG11202101157VA (en) | 2018-08-09 | 2021-03-30 | Bioverativ Therapeutics Inc | Nucleic acid molecules and uses thereof for non-viral gene therapy |
| JP7644007B2 (ja) | 2018-12-06 | 2025-03-11 | バイオベラティブ セラピューティクス インコーポレイテッド | 第ｉｘ因子を発現するレンチウイルスベクターの使用 |
| CA3152600A1 (en) | 2019-09-30 | 2021-04-08 | Andrew KROETSCH | Lentiviral vector formulations |
| JP2023537565A (ja) | 2020-06-24 | 2023-09-04 | バイオベラティブ セラピューティクス インコーポレイテッド | タンパク質を発現するように改変されたレンチウイルスベクターの調製物から遊離第ｖｉｉｉ因子を除去する方法 |
| JPWO2022030580A1 (enrdf_load_stackoverflow) * | 2020-08-06 | 2022-02-10 | ||
| EP4603587A1 (en) * | 2022-10-11 | 2025-08-20 | JCR Pharmaceuticals Co., Ltd. | Fusion protein of serum albumin and physiologically-active protein |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003060071A2 (en) * | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| CA2513213C (en) * | 2003-01-22 | 2013-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| CA2554089C (en) * | 2004-02-09 | 2013-10-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20060051859A1 (en) * | 2004-09-09 | 2006-03-09 | Yan Fu | Long acting human interferon analogs |
-
2006
- 2006-07-31 WO PCT/US2006/029391 patent/WO2007021494A2/en active Application Filing
- 2006-07-31 BR BRPI0614761-5A patent/BRPI0614761A2/pt not_active IP Right Cessation
- 2006-07-31 CA CA002618476A patent/CA2618476A1/en not_active Abandoned
- 2006-07-31 JP JP2008526056A patent/JP2009504157A/ja not_active Withdrawn
- 2006-07-31 AU AU2006280312A patent/AU2006280312A1/en not_active Abandoned
- 2006-07-31 KR KR1020087006077A patent/KR20080071119A/ko not_active Withdrawn
- 2006-07-31 EP EP06813242A patent/EP1924596A4/en not_active Withdrawn
- 2006-07-31 MX MX2008001865A patent/MX2008001865A/es not_active Application Discontinuation
-
2008
- 2008-02-04 IL IL189246A patent/IL189246A0/en unknown
- 2008-02-11 TN TNP2008000064A patent/TNSN08064A1/en unknown
- 2008-03-07 MA MA30727A patent/MA29836B1/fr unknown
- 2008-03-10 NO NO20081233A patent/NO20081233L/no not_active Application Discontinuation
- 2008-03-12 EC EC2008008262A patent/ECSP088262A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA29836B1 (fr) | 2008-10-03 |
| IL189246A0 (en) | 2008-08-07 |
| CA2618476A1 (en) | 2007-02-22 |
| KR20080071119A (ko) | 2008-08-01 |
| WO2007021494A3 (en) | 2007-07-26 |
| BRPI0614761A2 (pt) | 2009-05-19 |
| ECSP088262A (es) | 2008-05-30 |
| AU2006280312A1 (en) | 2007-02-22 |
| EP1924596A4 (en) | 2009-07-29 |
| JP2009504157A (ja) | 2009-02-05 |
| EP1924596A2 (en) | 2008-05-28 |
| MX2008001865A (es) | 2008-04-15 |
| WO2007021494A2 (en) | 2007-02-22 |
| NO20081233L (no) | 2008-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN08064A1 (en) | Albumin fusion proteins | |
| MX2009002816A (es) | Proteinas de fusion de albumina. | |
| WO2007146038A3 (en) | Albumin fusion proteins | |
| WO2005077042A3 (en) | Albumin fusion proteins | |
| WO2005003296A3 (en) | Albumin fusion proteins | |
| WO2003060071A3 (en) | Albumin fusion proteins | |
| WO2001079444A3 (en) | Albumin fusion proteins | |
| WO2003059934A3 (en) | Albumin fusion proteins | |
| WO2003030821A3 (en) | Albumin fusion proteins | |
| ES2353814T3 (es) | Proteinas n-glicosiladas recombinantes de celulas procariotas. | |
| EA201690946A1 (ru) | Мутанты fgf21 и их применение | |
| EP3372617A3 (en) | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same | |
| EA201990619A1 (ru) | Fgf21 мутанты и их применение | |
| WO2005063820A3 (en) | Il-7 fusion proteins | |
| IN2012DN02981A (enrdf_load_stackoverflow) | ||
| MY150226A (en) | Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and medicinal use | |
| TW200724679A (en) | Treatment of disease using an improved regulated expression system | |
| WO2006017355A3 (en) | Improved aprotinin variants | |
| WO2007134907A3 (en) | Gm-csf gene therapy for treatment of crohn's disease using an improved regulated expression system | |
| WO2002097110A3 (en) | TUMOR ENDOTHELIAL MARKER 7α MOLECULES AND USES THEREOF | |
| WO2006110367A3 (en) | Methods and compositions for mycoplasma toxins |